Quintrio
Home

PHARMACEUTICAL PREPARATIONS

TransCode Therapeutics, Inc. Common Stock

RNAZ

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Last trade $1.40
Day change +$0.05 (+3.70%)
Day range $1.30 – $1.46
Volume 25,109
Market cap $23M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$22.86M
Price / earnings
—
Price / book
-0.83×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.42×

Profitability

Earnings per share
-$2.73
Return on assets
-30.65%
Return on equity
167.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.02×
Current ratio
1.97×
Quick ratio
1.97×
Cash ratio
1.55×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$22.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RNAZ, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.54M$2.22M$1.76M$1.4M$1.66M$951.65K$1.45M$938.03K
Research and development$3.69M$15.53M$5.48M$3.16M$2.57M$2.22M$3.64M$1.23M
Total operating expenses$6.79M$17.76M$16.03M$4.56M$4.22M$3.17M$5.09M$2.17M
Operating income-$6.79M-$17.76M-$16.03M-$4.56M-$4.22M-$3.17M-$5.09M-$2.17M
Interest expense$0$0-$542-$5.96K$0-$114-$1.83K-$10.79K
Income before taxes-$6.75M-$17.55M-$13.22M-$4.86M-$4.28M-$12.09M-$5.92M-$2.32M
Income taxes$300$231.31K$226.07K$0$0$0$0$0
Net income-$6.75M-$17.79M-$13.44M-$4.86M-$4.28M-$12.09M-$5.92M-$2.32M
Net income attributable to common shareholders-$6.87M-$19.51M-$15.05M-$4.86M-$4.28M-$12.09M-$5.95M-$2.32M
EBITDA-$6.77M-$17.73M-$7.19M-$4.56M-$4.21M-$3.16M-$5.08M-$2.15M
Basic earnings per share-$7.17-$21.28-$16.38-$5.82-$5.13-$70.16-$281.26-$146.06
Diluted earnings per share-$7.17-$21.28-$16.38-$5.82-$5.13-$70.16-$281.26-$146.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Natera Partners With TransCode to Advance Colorectal Cancer Trial

Natera announced a strategic collaboration with TransCode Therapeutics to use its Signatera MRD test for identifying eligible patients in a Phase 2a trial evaluating TTX-MC138, an investigational therapy targeting miR-10b in colorectal cancer patients. The partnership aims to accelerate patient enrollment by detecting residual cancer in patients with no detectable disease on imaging, addressing an unmet medical need in early cancer recurrence intervention.

GlobeNewswire Inc.

Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs

A comprehensive market report on checkpoint inhibitors covering 50+ companies and 60+ drugs in oncology. The report highlights key players like Bristol Myers Squibb, Genentech, and emerging companies such as OncoC4 and Transcode Therapeutics, with analysis of marketed therapies, pipeline products, and recent industry collaborations and acquisitions in the immuno-oncology space.

Benzinga

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors. Stover brings over 30 years of executive leadership experience in life sciences, drug development, and capital formation. He will join the Audit and Nominating Committees as the company advances its RNA and immuno-oncology pipeline for cancer treatment.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics announced the acquisition of Polynoma LLC, a biotechnology firm focused on immuno-oncology, and received a $25 million strategic investment from CK Life Sciences. The deal includes stock issuance and will support the advancement of TransCode's microRNA-based therapeutic into Phase 2 clinical trials.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 15, 20251-for-28reverse split
Dec 4, 20241-for-33reverse split
Jan 16, 20241-for-40reverse split
May 23, 20231-for-20reverse split